Clinical Trial Update: Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating silybin supplementation during hepatitis C therapy with pegylated interferon-α2b plus ribavirin found reduced depression and improved w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Silybin (silybin)

Snippet

Sponsor: University of Catania | Conditions: Work Ability, Depression | Phase 3 | Status: COMPLETED